This article has been clarified to note that Novartis discovered the gene marker linked to liver toxicities associated with lumiracoxib, not Novartis' diagnostics unit.

By Turna Ray

Cepheid and Novartis are collaborating on the development of a test for monitoring Bcr-Abl gene transcripts, which will help doctors more reliably manage Philadelphia chromosome-positive chronic myelogenous leukemia patients treated with Novartis' oncologic Gleevec.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Sciencethis week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.